Baidu
map

消化指南

订阅

MedSci主页 / 所有栏目 / 消化指南

2021 CSCO临床指南：胃癌的诊断和治疗（英文版）

中国临床肿瘤学会 中国临床肿瘤学会

治疗胃癌诊断

本文是2021年版中国临床肿瘤学会(CSCO)胃癌诊疗指南的英文版，该版指南在2020版指南基础上，更新内容融合了国内外过去一年的重大临床研究结果，注重中国人群研究数据，贴近本国临床实践。

中文标题：

2021 CSCO临床指南：胃癌的诊断和治疗（英文版）

英文标题：

The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021

发布机构：

中国临床肿瘤学会

发布日期：

简要介绍：

本文是2021年版中国临床肿瘤学会(CSCO)胃癌诊疗指南的英文版，该版指南在2020版指南基础上，更新内容融合了国内外过去一年的重大临床研究结果，注重中国人群研究数据，贴近本国临床实践。

相关资料下载：
[AttachmentFileName(sort=1, fileName=2021 CSCO临床指南：胃癌的诊断和治疗（英文版）.pdf)] GetToolGuiderByIdResponse(projectId=1, id=a97061c00212583c, title=2021 CSCO临床指南：胃癌的诊断和治疗（英文版）, enTitle=The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021, guiderFrom=中国临床肿瘤学会, authorId=0, author=, summary=本文是2021年版中国临床肿瘤学会(CSCO)胃癌诊疗指南的英文版，该版指南在2020版指南基础上，更新内容融合了国内外过去一年的重大临床研究结果，注重中国人群研究数据，贴近本国临床实践。, cover=https://img.medsci.cn/202175/1625470678288_5433779.jpeg, journalId=0, articlesId=null, associationId=863, associationName=中国临床肿瘤学会, associationIntro=null, copyright=0, guiderPublishedTime=null, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">本文是2021年版中国临床肿瘤学会(CSCO)胃癌诊疗指南的英文版，该版指南在2020版指南基础上，更新内容融合了国内外过去一年的重大临床研究结果，注重中国人群研究数据，贴近本国临床实践。</span></p>, tagList=[TagDto(tagId=65, tagName=治疗), TagDto(tagId=438, tagName=胃癌), TagDto(tagId=757, tagName=诊断)], categoryList=[CategoryDto(categoryId=4, categoryName=消化, tenant=100), CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=76, categoryName=胃肠外科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=20620, categoryName=肿瘤医学网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=438, articleKeyword=胃癌, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=15200, appHits=942, showAppHits=0, pcHits=2348, showPcHits=14254, likes=4, shares=74, comments=40, approvalStatus=1, publishedTime=Mon Jul 05 15:40:21 CST 2021, publishedTimeString=null, pcVisible=1, appVisible=1, editorId=5433779, editor=Oranhyg是正经人, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=Oranhyg是正经人, createdTime=Mon Jul 05 15:38:09 CST 2021, updatedBy=5433779, updatedName=Oranhyg是正经人, updatedTime=Sat Jan 06 17:44:46 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 CSCO临床指南：胃癌的诊断和治疗（英文版）.pdf)])
2021 CSCO临床指南：胃癌的诊断和治疗（英文版）.pdf
下载请点击：
评论区 (26)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1202750, encodeId=3f071202e5024, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58005647136, createdName=吴卓远108, createdTime=Tue Mar 15 12:59:56 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197311, encodeId=f5f1119e311d0, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ec5442075, createdName=ms4000001880486183, createdTime=Fri Feb 25 21:00:07 CST 2022, time=2022-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066799, encodeId=9ed91066e999f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8275631105, createdName=ms2000000908561621, createdTime=Thu Nov 04 07:54:56 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063254, encodeId=1b9d106325411, content=有中文吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dd55645817, createdName=ms6000000590698351, createdTime=Sat Oct 23 21:48:19 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060130, encodeId=e69b1060130f7, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3a025241534, createdName=147c0641m47暂无昵称, createdTime=Wed Oct 13 14:33:55 CST 2021, time=2021-10-13, status=1, ipAttribution=)]
    2022-03-15 吴卓远108

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1202750, encodeId=3f071202e5024, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58005647136, createdName=吴卓远108, createdTime=Tue Mar 15 12:59:56 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197311, encodeId=f5f1119e311d0, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ec5442075, createdName=ms4000001880486183, createdTime=Fri Feb 25 21:00:07 CST 2022, time=2022-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066799, encodeId=9ed91066e999f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8275631105, createdName=ms2000000908561621, createdTime=Thu Nov 04 07:54:56 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063254, encodeId=1b9d106325411, content=有中文吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dd55645817, createdName=ms6000000590698351, createdTime=Sat Oct 23 21:48:19 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060130, encodeId=e69b1060130f7, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3a025241534, createdName=147c0641m47暂无昵称, createdTime=Wed Oct 13 14:33:55 CST 2021, time=2021-10-13, status=1, ipAttribution=)]
    2022-02-25 ms4000001880486183

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1202750, encodeId=3f071202e5024, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58005647136, createdName=吴卓远108, createdTime=Tue Mar 15 12:59:56 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197311, encodeId=f5f1119e311d0, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ec5442075, createdName=ms4000001880486183, createdTime=Fri Feb 25 21:00:07 CST 2022, time=2022-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066799, encodeId=9ed91066e999f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8275631105, createdName=ms2000000908561621, createdTime=Thu Nov 04 07:54:56 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063254, encodeId=1b9d106325411, content=有中文吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dd55645817, createdName=ms6000000590698351, createdTime=Sat Oct 23 21:48:19 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060130, encodeId=e69b1060130f7, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3a025241534, createdName=147c0641m47暂无昵称, createdTime=Wed Oct 13 14:33:55 CST 2021, time=2021-10-13, status=1, ipAttribution=)]
    2021-11-04 ms2000000908561621

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1202750, encodeId=3f071202e5024, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58005647136, createdName=吴卓远108, createdTime=Tue Mar 15 12:59:56 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197311, encodeId=f5f1119e311d0, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ec5442075, createdName=ms4000001880486183, createdTime=Fri Feb 25 21:00:07 CST 2022, time=2022-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066799, encodeId=9ed91066e999f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8275631105, createdName=ms2000000908561621, createdTime=Thu Nov 04 07:54:56 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063254, encodeId=1b9d106325411, content=有中文吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dd55645817, createdName=ms6000000590698351, createdTime=Sat Oct 23 21:48:19 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060130, encodeId=e69b1060130f7, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3a025241534, createdName=147c0641m47暂无昵称, createdTime=Wed Oct 13 14:33:55 CST 2021, time=2021-10-13, status=1, ipAttribution=)]
    2021-10-23 ms6000000590698351

    有中文吗

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1202750, encodeId=3f071202e5024, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58005647136, createdName=吴卓远108, createdTime=Tue Mar 15 12:59:56 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197311, encodeId=f5f1119e311d0, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0ec5442075, createdName=ms4000001880486183, createdTime=Fri Feb 25 21:00:07 CST 2022, time=2022-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066799, encodeId=9ed91066e999f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8275631105, createdName=ms2000000908561621, createdTime=Thu Nov 04 07:54:56 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063254, encodeId=1b9d106325411, content=有中文吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0dd55645817, createdName=ms6000000590698351, createdTime=Sat Oct 23 21:48:19 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060130, encodeId=e69b1060130f7, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3a025241534, createdName=147c0641m47暂无昵称, createdTime=Wed Oct 13 14:33:55 CST 2021, time=2021-10-13, status=1, ipAttribution=)]
    2021-10-13 147c0641m47暂无昵称

    学习了

    0

以上为热门评论，梅斯医学App还有更多内容

相关指南

2017 嗜酸性筋膜炎的诊断标准，严重性分级和治疗指南

国外皮肤性病相关专家小组（统称） · 2017-12-13

2017 ASA立场声明：成人失眠症的心理/行为治疗

澳大拉西亚睡眠协会(ASA,Australasian Sleep Association) · 2017-06-20

2017 NAMS立场声明：激素治疗

北美绝经学会(NAMS,The North American Menopause Society) · 2017-06-24

解读2015年美国风湿病学会强直性脊柱炎和放射学阴性中轴型脊柱关节炎新的治疗推荐

暂未更新 · 2016-07-30

中国成人艰难梭菌感染诊断和治疗专家共识

暂未更新 · 2017-06-20

2016年中国超重/肥胖医学营养治疗专家共识解读

暂未更新 · 2017-05-30

拓展阅读

【今日分享】2024版CACA胃癌整合诊治指南（精简版）

旨在及时更新发布一部科学、规范且实用性强的诊疗指南，能够为全国医疗工作者提供有力的指导工具，助力中国胃癌防治工作更加精准高效，显著改善患者预后，为健康中国战略的深入实施贡献力量。

NEJM：曲妥珠单抗联合帕博利珠单抗治疗HER2阳性胃癌，OS结果

人类表皮生长因子受体 2（HER-2）是胃癌的重要靶点之一，我国胃癌患者 HER-2 阳性率为 12%～13%[1,2]。2010 年，ToGA 研究首次证实抗 HER-2 治疗联合化疗可显著改善 H

NEJM：徐瑞华团队发现靶向Claudin 18.2的zolbetuximab能显著延长晚期胃癌生存期

根据今年2月份中国国家癌症中心（NCC）发布的2022年中国新发癌症病例数和死亡人数数据：2022年，

约30%胃癌患者检出同源重组（HR）基因变异，能否预测一线铂类化疗疗效？

研究探索 HRD 胃癌临床病理特征及在一线铂类化疗中的意义。HRD 组肿瘤有独特特征且对铂类化疗反应更好，或可作为预测标志物，需大规模研究验证其临床效用。

Mol Cancer：江苏大学张徐等团队合作发现N2 TANs外泌体在体外和体内促进胃癌转移

该研究首次阐明了N2 TANs外泌体在体外和体内促进胃癌转移。

梁寒教授：根除幽门螺杆菌治疗 能够使胃癌发生风险降低 46%

为扩大肿瘤防控宣传，深入普及肿瘤防控知识，中国抗癌协会特邀天津医科大学肿瘤医院胃癌中心主任梁寒教授为我们分享关于胃癌的最新现状，以及如何有效防治幽门螺杆菌——这一与胃癌发生密切相关的细菌。

Baidu
map
Baidu
map
Baidu
map